[關(guān)鍵詞]
[摘要]
目的 分析甲潑尼龍聯(lián)合阿奇霉素治療兒童支原體肺炎的安全性及療效,為臨床治療提供指導。方法 選取2015年12月-2016年12月上海交通大學醫(yī)學院附屬新華醫(yī)院收治的200例支原體肺炎患兒作為研究對象。隨機分為觀察組及對照組,每組各100例。兩組患兒均接受營養(yǎng)支持、糾正酸堿代謝失衡、吸氧等常規(guī)對癥處理。對照組患兒在常規(guī)治療基礎上接受阿奇霉素靜脈滴注治療,觀察組患兒在常規(guī)治療基礎上接受甲潑尼龍聯(lián)合阿奇霉素靜脈滴注治療。7 d為1個療程,連續(xù)治療3個療程。比較兩組患兒的治療效果及不良反應發(fā)生情況。結(jié)果 治療3療程后,觀察組患兒治療總有效率顯著高于對照組,差異有統(tǒng)計學意義(P<0.05);觀察組患兒肺啰音消失時間、退熱時間、咳嗽緩解時間及住院時間等指標均顯著優(yōu)于對照組,差異有統(tǒng)計學意義(P<0.05)。治療1周后,兩組患兒各血清炎癥因子水平均較治療前出現(xiàn)顯著下降,同組治療前后比較差異有統(tǒng)計學意義(P<0.05);且觀察組患兒各指標顯著低于對照組,差異有統(tǒng)計學意義(P<0.05)。兩組患兒總不良反應發(fā)生率相比較無顯著差異。結(jié)論 甲潑尼龍聯(lián)合阿奇霉素治療兒童支原體肺炎,可提高治療效果,快速降低機體炎癥反應,安全可靠,臨床效果更好。
[Key word]
[Abstract]
Objective To observe the safety and efficacy of methylprednisolone combined with azithromycin in children with mycoplasma pneumonia.Methods 200 children with mycoplasma pneumonia December 2015 to December 2016 in our hospital were selected and randomly divided into observation group and control group, 100 cases in each group. Both groups received routine symptomatic treatment. In control group, children were treated with intravenous infusion of azithromycin, in observation group, children received azithromycin combined with methylprednisolone intravenous infusion. The effect were compared.Results After treatment for 3 courses, the total effective rate of the observation group was significantly higher than that of the control group (P < 0.05); the symptoms subsided time and hospitalization time were significantly lower in the observation group than in the control group (P < 0.05); after 1 week of treatment, the levels of serum inflammatory factors in the two groups were significantly lower than those before treatment (P < 0.05), and the degree of decline of the indexes in the observation group was more obvious (P < 0.05); there was no significant difference in the total number of adverse reactions between the two groups.Conclusion Azithromycin combined with methylprednisolone treatment of children with mycoplasma pneumonia, can improve the treatment effect, safe and reliable, worthy of clinical promotion.
[中圖分類號]
[基金項目]